| IPO Company Profile |
| Current Quote | News | SEC Filings | Peer IPO Companies |
| Abgenix, Inc. |
| 7601 Dumbarton Circle, Fremont, CA 94555 * (510) 608-6500 |
| The company develops and intends to commercialize antibody therapeutic products for the prevention and treatment of a variety of disease conditions, including transplant-related diseases, inflammatory and autoimmune disorders, and cancer. |
| Manager | Tier | Phone |
| BancAmerica Robertson Stephens | Lead Manager | (415) 989-8500 |
| Lehman Brothers Incorporated | Co-manager | (212) 526-8100 |
| NASNTL: | ABGX | Manufacturing: | SIC 2836 | |
| Type of Shares: | Common Shares | Filing Date: | 4/3/98 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 7/2/98 | |
| Non-U.S. Shares: | 0 | Filing Range: | $8.00 - $10.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $8.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.56 | |
| Offering Amount: | $22,500,000 | Selling: | $0.32 | |
| Expenses: | $750,000 | Reallowance: | $0.10 | |
| Post-IPO Shares: | 11,077,894 | |||
| Spin out parent firm: | Cell Genesys Inc. | |||
| Issuer's Law Firm: | Wilson, Sonsini, Goodrich & Rosati |
| Bank's Law Firm: | Cooley Godward Castro Huddleson & Tatum |
| Registrar/Transfer Agent: | ChaseMellon Shareholder Services, L.L.C. |
| Auditor: | Ernst & Young |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Audited Income | Balance Sheet | ||
| 12/31/97 | 12/31/97 | ||||
| Revenue: | $1.95 | Assets: | $22.08 | ||
| Net Income: | -$35.88 | Curr Assets: | $15.87 | ||
| EPS: | -$9.22 | Liabilities: | $44.40 | ||
| Prior EPS: | Curr Liab: | $9.23 | |||
| Cash Flow/Oper: | -$10.18 | Equity: | -$22.32 | ||
| Cash Flow/Fin: | $21.05 | Cash: | $15.32 | ||
| Cash Flow/Inv: | -$13.44 | Working Cap: | $6.64 | ||
| Use of Proceeds |
| The proceeds from the proposed offering will be used for research and development, working capital and general corporate purposes. |